Also called: Meningococcal Infections
Important: This page is general information, not medical advice. It does not recommend or prescribe any treatment. Always consult your doctor or pharmacist before starting, stopping or changing any medicine.
About Meningococcal Disease
Meningococcal disease is the name for any illness that is caused by Neisseria meningitidis bacteria (also called meningococcal bacteria). These illnesses are often severe and can sometimes be deadly. They include infections of the lining of the brain and spinal cord (meningitis) and in the bloodstream (sepsis). Vaccines can help prevent the disease.
Some people have Neisseria meningitidis, the bacteria that cause the disease, in the back of their nose and throat. They usually have the bacteria but don't get sick. This is called being a "carrier." But sometimes the bacteria can spread to other parts of the body and cause meningococcal disease.
The bacteria can spread from person to person through saliva (spit). It usually happens through close or lengthy contact with a person who has it. Close contact can include things like kissing and coughing.
You cannot catch the bacteria through casual contact with someone who has the disease. For example, you cannot get it by breathing air where that person has been.
Anyone can get meningococcal disease, but you are more likely to get it if someone you live with has it. You are also more likely to get it if you have direct contact with the saliva of someone who has it (like through kissing).
Also, certain groups of people are more likely to get the disease. They include:
- Children younger than 1 year old.
- Teens and young adults ages 16 through 23 years old.
- Adults 65 years and older.
- People with medical conditions that weaken their immune system, including those with HIV and certain rare immune system diseases.
- People who either don't have a spleen or have a spleen that does not function well.
- People who take complement inhibitor. These are immunotherapy medicines that are given to people with certain rare conditions.
- People who live in crowded settings, such as college dorms or military barracks.
- People who travel to areas where the disease is more common, such as certain parts of sub-Saharan Africa.
There are different types of meningococcal disease. The most common types are meningitis and septicemia. Both types are very serious and can be deadly in a matter of hours.
Meningococcal meningitis is a meningococcal infection of the lining of the brain and spinal cord. The most common symptoms include:
- Fever
- Headache
- Stiff neck
It can also cause symptoms such as:
- Nausea and vomiting
- Photophobia (your eyes being more sensitive to light)
- Confusion
It may be hard to notice these symptoms in newborns and babies. They can also have different symptoms. They may:
- Be slow or inactive
- Be irritable
- Vomit
- Feed poorly
- Have a bulging of the soft spot of their skull
Meningococcal septicemia is a meningococcal infection of the bloodstream. It's also called meningococcemia. When someone has this disease, the bacteria enter the bloodstream and multiply. This damages the walls of the blood vessels and causes bleeding into the skin and organs. The symptoms may include:
- Fever and chills
- Fatigue
- Vomiting
- Cold hands and feet
- Severe aches or pain in the muscles, joints, chest, or abdomen (belly)
- Rapid breathing
- Diarrhea
- A dark purple rash (in the later stages of the disease)
Because it is so serious, you need to seek immediate medical attention if you or your child develops the symptoms of meningococcal disease.
The signs and symptoms of meningococcal disease are often similar to those of other illnesses. This can make it hard to diagnose.
If your (or your child's) health care provider thinks that you or your child could have meningococcal disease, they will order tests that take samples of blood and/or cerebrospinal fluid (fluid near the spinal cord). They will send the samples to a lab for testing. The testing will include bacteria culture testing, which can identify the specific type of bacteria that is causing the infection. Knowing this can help the provider decide on the best treatment.
Certain antibiotics can treat meningococcal disease. It is important that treatment is started as soon as possible. So if the provider thinks you have meningococcal disease, they will give you antibiotics right away (before the test results come back).
People with serious disease may need additional treatments, such as:
- Breathing support
- Medicines to treat low blood pressure
- Surgery to remove dead tissue
- Wound care for parts of the body with damaged skin
Some people with meningococcal disease will have long-term health problems and disabilities. These may include:
- Loss of limb(s)
- Deafness
- Nervous system problems
- Brain damage
Even with treatment, 10 to 15 in 100 people will die from the disease.
The best way to prevent meningococcal disease is to get vaccinated. The U.S. Centers for Disease Control and Prevention (CDC) recommends meningococcal vaccination for:
- All preteens and teens
- Children at higher risk for meningococcal disease
- Adults at higher risk for meningococcal disease
If you are a close contact of a person with meningococcal disease, you will likely be given antibiotics to prevent you from getting sick. This is called "prophylaxis." Close contacts include people who are living together. They also include people who had direct contact with the saliva of a person who has the disease (such as from kissing).
Although it's rare, you can get meningococcal disease more than once.
Centers for Disease Control and Prevention
It sits within Infections.
The lead U.S. institute for this subject is the National Institute of Allergy and Infectious Diseases.
When to speak to someone. Reading about a topic cannot tell you whether it applies to you. Speak to a doctor or pharmacist if symptoms are severe, sudden, getting worse, or simply not going away — and seek emergency care immediately for chest pain, breathing difficulty, sudden weakness or confusion, or a serious allergic reaction.
Research on Meningococcal Disease
368 studies areregistered for this condition on ClinicalTrials.gov, the U.S. National Library of Medicine's public registry. A selection is below — the links go straight to the registry entry, not to a summary of ours.
What a registered study does and does not mean. Registration means a study exists and has been declared publicly. It says nothing about whether the treatment being tested works, is safe, or is available to you. Many studies find no benefit — that is what research is for. Never seek out an experimental treatment on the strength of a registry entry alone.
Research currently under way
- Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Infants and Toddlers in ChinaSanofi
- Metagenomic Analysis of the Pharynx in High Risk PartnersGuy's and St Thomas' NHS Foundation Trust
- Evaluation of the Antibody Persistence Beyond Five Years After Immunization With MenFiveTM (NmCV-5), a Pentavalent Meningococcal ACYWX Conjugate VaccineSerum Institute of India Pvt. Ltd.
- Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healthy Children and Adolescents in ChinaSanofi
- National Bacterial Meningitis Study in Children and NewbornsAssociation Clinique Thérapeutique Infantile du val de Marne
- Immunogenicity and Safety of MenB Vaccine in Pediatric Patients With Autoimmune Rheumatic DiseasesUniversity of Sao Paulo General Hospital
Research already completed
- Safety and Efficacy Study of Meningococcal Group B Vaccine rMenB+OMV NZ (Bexsero) to Prevent Gonococcal InfectionNational Institute of Allergy and Infectious Diseases (NIAID)
- A Study on the Safety, Tolerability and Immune Response of Meningococcal Combined ABCWY Vaccine in Healthy InfantsGlaxoSmithKline
- Azithromycin for Meningococcal CarriageEmory University
- Understanding the Immune Response to Two Different Meningitis VaccinesUniversity of Oxford
- A Phase 3 Study to Assess the Immune Response And Safety Of Rmenb+Omv Nz In Primed Healthy Participants (10 To 20 Years Old)GlaxoSmithKline
- Meningococcal Serogroup ACYWX Conjugate Vaccine in Comparison With MenACWY-TT Conjugate VaccineEmory University
Study data from ClinicalTrials.gov, a service of the U.S. National Library of Medicine. Retrieved 2026-07-30. Registry entries are supplied by study sponsors and investigators; ClinicalTrials.gov does not verify their scientific validity. PocketsInfo is not affiliated with, and not endorsed by, the NLM or the NIH.
Where to read more
Rather than paraphrase, we point you to the primary sources. Every link below is to a government health agency, a national institute or a recognised medical body — grouped by what you are trying to find out.
Start Here
- About Meningococcal DiseaseCenters for Disease Control and Prevention
Symptoms
- Meningococcal Disease Symptoms and ComplicationsCenters for Disease Control and Prevention
Diagnosis and Tests
- Bacteria Culture TestNational Library of Medicine
- Meningococcal Disease TestsNational Library of Medicine
- Spinal Tap (Lumbar Puncture)Nemours Foundation
Prevention and Risk Factors
- Meningococcal ACWY Vaccine: What You Need to KnowCenters for Disease Control and Prevention
- Meningococcal Vaccine SafetyCenters for Disease Control and Prevention
Related Issues
- Meningococcal Disease: CausesCenters for Disease Control and Prevention
- Travelers' Health: Meningococcal DiseaseCenters for Disease Control and Prevention
Clinical Trials
- ClinicalTrials.gov: Meningococcal InfectionsNational Institutes of Health
Medical subject headings
Clinicians and researchers index this subject under Meningococcal Infections. These are the terms to use when searching medical literature.
This page is built from the MedlinePlus health topic record for Meningococcal Disease, a service of the U.S. National Library of Medicine (NLM), National Institutes of Health. Information is from MedlinePlus.gov. PocketsInfo is not affiliated with, and is not endorsed by, the NLM or the NIH. Retrieved 30 July 2026.